MitoSense, Inc.

‍

In December 2023, we invested in MitoSense, Inc., a research and development company discovering treatments for neurodegenerative diseases. 

Research efforts for the last 10 years have been devoted to mitochondrial dysfunction in cancer, which led to evaluation of it in neurodegenerative diseases.  This resulted in the discovery and development of Mitochondria Organelle Transplantation (MOT™) technology. They have successfully demonstrated proof of concept for this cellular biotherapy which holds great promise for millions suffering from neurodegenerative diseases such as ALS, Parkinson's, Huntington’s, Alzheimer's, and other neurodegenerative diseases. 

More information about MitoSense, Inc.